Drugs / Liposome doxorubicin
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 2 | NCT06412068 Background | Jun 2024 → Jun 2026 | primary mediastinal large B-cell lymphoma | Sun Yat-sen University | Unknown | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Liposome doxorubicin | “Doxorubicin,50mg／㎡ （or Liposome doxorubicin ，40 mg／㎡）,d2,intravenous drip” NCT06412068 ↗ |
| Route | Intravenous | “intravenous drip” NCT06412068 ↗ |